Download Mendeley(2S,3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1,2,4]triazolo[1,5-a]- pyridin-6-ylphenyl)butanamide: a selective alpha-amino amide dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Edmondson, S.D., Mastracchio, A., Mathvink, R.J., He, J., Harper, B., Park, Y.J., Beconi, M., Di Salvo, J., Eiermann, G.J., He, H., Leiting, B., Leone, J.F., Levorse, D.A., Lyons, K., Patel, R.A., Patel, S.B., Petrov, A., Scapin, G., Shang, J., Roy, R.S., Smith, A., Wu, J.K., Xu, S., Zhu, B., Thornberry, N.A., Weber, A.E.(2006) J Med Chem 49: 3614-3627
- PubMed: 16759103
- DOI: https://doi.org/10.1021/jm060015t
- Primary Citation of Related Structures:
2FJP - PubMed Abstract:
A series of beta-substituted biarylphenylalanine amides were synthesized and evaluated as inhibitors of dipeptidyl peptidase IV (DPP-4) for the treatment of type 2 diabetes. Optimization of the metabolic profile of early analogues led to the discovery of (2S,3S)-3-amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1,2,4]triazolo[1,5-a]pyridin-6-ylphenyl)butanamide (6), a potent, orally active DPP-4 inhibitor (IC(50) = 6.3 nM) with excellent selectivity, oral bioavailability in preclinical species, and in vivo efficacy in animal models. Compound 6 was selected for further characterization as a potential new treatment for type 2 diabetes.
Organizational Affiliation:
Department of Medicinal Chemistry, Merck Research Laboratories, Merck & Co., Inc., Rahway, New Jersey 07065, USA. scott_edmondson@merck.com
